Mydayis’ debut this weekend at the 30th US Psychiatric and Mental Health Congress in New Orleans, Louisiana, came after more than a decade of studies for the treatment for attention deficit hyperactivity disorder (ADHD). During the meeting, Shire PLC presented consolidated data involving adults aged 18 to 55 years; in June, FDA approved the drug for patients as young as 13. The drug has the same active ingredient as Adderall XR, but works up to 16 hours through a 3-bead technology that releases amphetamine in the stomach and at points in the small intestine over several hours.